Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 5;230(2):e405–e415. doi: 10.1093/infdis/jiad434

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 4. — CD4⁺ T-cell responses as measured by intracellular cytokine staining. The CD4⁺ T-cell responses rate (numbers above graph) and magnitude (boxplots) 2 weeks after (month 6.5) and 6 months after (month 12) the final immunization for each treatment arm for the following vaccine-matched antigens: subtype C 96ZM651 gp120, 1086 B2 gp120, and subtype C TV1 gp120. Numbers above indicate responders/total and percent. The median and boxplots (which display the first and third quartiles, whiskers indicate variability) are based on positive responders only (shown as filled circles), negative responders (below background) are shown as open symbols. Treatment groups are 200 µg Pr + MF59, 200 µg Pr + AS01_B, 40 µg Pr + AS01_B, and placebo. Abbreviations: gp, glycoprotein; IFN-γ, interferon-γ; IL-2, interleukin 2; Pr, protein.